Market Overview

Mallinckrodt Downgraded By Raymond James On Lack Of 'Rational Valuation Framework'

Share:
Mallinckrodt Downgraded By Raymond James On Lack Of 'Rational Valuation Framework'
Related
28 Stocks Moving In Monday's Pre-Market Session
FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation
Massachusetts AG after Purdue Pharma owners for role in opioid crisis (Seeking Alpha)

Raymond James downgraded Mallinckrodt Public Limited Company (NYSE: MNK) on valuation after the drugmaker's second-quarter report. 

The Analyst

Raymond James analyst Elliot Wilbur downgraded Mallinckrodt from Outperform to Market Perform.

The Thesis

The Q2 print demonstrates Mallinckrodt's resilience, as sales of HP Acthar were in line with projections, Wilbur said in a Wednesday note. (See his track record here.) 

Sales of the drug increased 20 percent sequentially and an imminent decline seems unlikely, the analyst said. 

"We are increasing our 2018 and 2019 adjusted EPS projections to $6.54 and $7.52, from $6.04 and $7.10, respectively, to account for [Q2] over performance, increased full-year 2018 guide and modest increases to 2019 top line expectations," Wilbur said. 

Raymond James is incorporating initial pipeline expectations in its post-2020 assumptions for the pharmaceutical company.

Wednesday's downgrade is driven by the absence of a "rational valuation framework" to support significant upside to the stock, the analyst said. 

“While pipeline optionality remains high with [the] valuation heavily discounting [the] potential to meaningfully buffer declining base product trends, even with [a] probability-adjusted contribution incorporated in post-2021 numbers, we expect EBITDA levels to drop meaningfully post-2020." 

Price Action

Mallinckrodt shares were trading down 1.05 percent to $29.13 at the time of publication Wednesday. 

Related Links:

Analyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar

Here's Why Barclays Downgraded Mallinckrodt

Latest Ratings for MNK

DateFirmActionFromTo
Dec 2018MizuhoMaintainsNeutralNeutral
Nov 2018Canaccord GenuityUpgradesHoldBuy
Sep 2018BerenbergInitiates Coverage OnSell

View More Analyst Ratings for MNK
View the Latest Analyst Ratings

Posted-In: Elliot Wilbur Raymond JamesAnalyst Color Earnings News Downgrades Analyst Ratings General Best of Benzinga

 

Related Articles (MNK)

View Comments and Join the Discussion!

Q2 Earnings Preview For ACADIA Pharmaceuticals

Jack In The Box Q3 Earnings Preview